Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.WuXi PharmaTech has completed the acquisition of China based contract clinical research services companies,MedKey Med-Tech Development and Jiecheng Med-Tech Development.
Subscribe to our email newsletter
Both the companies offer services in regulatory affairs, Phase I-IV clinical trial management, and clinical trial site management in China.
As part of the acquisition, MedKey/Jiecheng will increase WuXi’s customer base and will focus on clinical services needed by customers for Chinese regulatory filings and market access.
WuXi chairman and CEO Ge Li said its acquisition of Medkey/Jiecheng continues their strategy to build an integrated platform of R&D services that will allow anyone and any company to discover and develop drugs more efficiently and cost effectively for patients.